Introduction: Our study aimed to evaluate temporomandibular joint involvement in rheumatoid arthritis (RA) patients and healthy individuals Methods: 142 participants were recruited in two groups: 72 patients with RA and 70 healthy controls. All participants were tested for seropositivity of rheumatoid factor and anticitrullinated protein antibodies. TMD diagnosis was determined according to the standardized and validated diagnostic criteria for TMD (DC/TMD): myalgia, arthralgia, articular disc, displacement, degenerative joint disease, and headache attributed to TMD. Bruxism, a probable sleep and/or awake bruxism diagnosis was determined based on self-report and several clinical findings. Results: The prevalence of TMD was 44.44% in RA patients and 34.28% in the control group (P < 0.005). TMD-pain diagnosis presented either as myalgia, arthralgia, or both and for those who are having a degenerative joint disease. Within the RA group, seronegative patients had a TMD-pain diagnosis significantly more often than seropositive patients (P = 0.048).75% of participants used analgesics, especially paracetamol, during the last 24 h, without differences between participants with TMD-pain diagnosis or without (P = 0.759). No difference was found between the groups in maximum mouth opening, protrusion, and laterotrusion. There was reported no difference in probable sleep bruxism diagnosis between participants with TMD diagnosis and those without (P = 0.223). Conclusion: The prevalence of TMD pain is increased in seronegative RA patients and is associated with bruxism signs and symptoms. Health professionals should be alert to TMD pain in RA patients.
Read full abstract